Veracyte (VCYT) | Stock Overview & Key Data
Veracyte Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $86.03 on February 8, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Veracyte
VCYT
|
2.74B Mid-cap | 9.46% | 45.59% | 38.83% | 1.99% | 14.89% | 74.15% | 73.43% | 40.68% | 774.34% | 276.75% | 276.75% |
|
Thermo Fisher
TMO
|
174.55B Large-cap | 3.89% | 2.45% | -6.72% | -18.35% | -20.01% | 22.27% | -5.31% | 9.75% | 222.18% | 684.25% | 1,233.99% |
|
Danaher
DHR
|
126.39B Large-cap | 2.86% | 2.32% | -12.71% | -22.05% | -22.71% | -3.81% | -12.18% | -14.95% | 176.52% | 423.71% | 744.91% |
|
Revvity
RVTY
|
9.74B Mid-cap | 4.42% | 16.83% | 5.34% | -2.12% | 2.98% | 15.63% | -9.26% | -24.76% | 91.55% | 296.02% | 399.05% |
|
Icon plc
ICLR
|
8.98B Mid-cap | 21.49% | 28.52% | 32.38% | -23.37% | -23.73% | 4.44% | -38.55% | -38.28% | 98.58% | 437.40% | 897.58% |
|
Charles River
CRL
|
8.28B Mid-cap | 9.35% | 4.38% | 2.38% | -2.60% | -11.14% | 33.24% | -9.95% | -46.35% | 110.50% | 383.44% | 347.52% |
Ownership & Short Interest
Calculate Your Veracyte Investment Returns
Long-Term Investment Performance Analysis
Veracyte stock price in May 2016 was $5.30, A $1,000.00 lump sum investment in Veracyte made 10 years ago would be worth approximately $9,188.68 today, representing a exceptional return of 818.87%. This translates to an annualized return (CAGR) of 24.81%.
10 Years Investment Scenario (May 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is VCYT's 52-week high and low?
- In the last 52 weeks, Veracyte reached a high of $50.71 (on November 25, 2025) and a low of $22.61 (on July 18, 2025).
- What is the market cap and P/E ratio for VCYT?
- Curious about Veracyte's size and valuation? Its market capitalization stands at 2.74B. When it comes to valuation, the P/E ratio (trailing twelve months) is 40.43, and the forward P/E (looking ahead) is 18.80.
- Does VCYT pay dividends? If so, what's the yield?
- As for dividends, Veracyte isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Veracyte's main competitors or similar companies to consider before investing?
When looking at Veracyte, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Thermo Fisher
TMO174.55B Healthcare Diagnostics & Research 22.27% -5.31% Danaher
DHR126.39B Healthcare Diagnostics & Research -3.81% -12.18% Revvity
RVTY9.74B Healthcare Diagnostics & Research 15.63% -9.26% Icon plc
ICLR8.98B Healthcare Diagnostics & Research 4.44% -38.55% Charles River
CRL8.28B Healthcare Diagnostics & Research 33.24% -9.95% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Veracyte Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Veracyte's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 5.34%, the Debt to Equity ratio from the most recent quarter is 3.03, and its Gross Profit Margin stands at 72.51%.
- What is the recent revenue and earnings growth for VCYT?
- Looking at Veracyte's growth, its revenue over the trailing twelve months (TTM) was $517M. Compared to the same quarter last year (YoY), quarterly revenue grew by 18.50%, and quarterly earnings saw a YoY growth of 704.80%.
- How much of VCYT stock is held by insiders and institutions?
- Wondering who owns Veracyte stock? Company insiders (like executives and directors) hold about 1.00% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 110.26%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.